These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26990573)

  • 1. Biologic Therapeutic Drug Monitoring in Australia.
    J Connor S
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():8-9. PubMed ID: 26990573
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study.
    Wang Z; Verstockt B; Sabino J; Ferrante M; Vermeire S; Dreesen E
    Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3188-3190.e2. PubMed ID: 36640805
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunosuppression in inflammatory bowel disease: When, how and how long?].
    Gross V
    Dtsch Med Wochenschr; 2012 Sep; 137(37):1803-5. PubMed ID: 22956222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring in inflammatory bowel disease.
    Jossen J; Dubinsky M
    Curr Opin Pediatr; 2016 Oct; 28(5):620-5. PubMed ID: 27583410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of adalimumab in Crohn's disease.
    Ternant D; Karmiris K; Vermeire S; Desvignes C; Azzopardi N; Bejan-Angoulvant T; van Assche G; Paintaud G
    Eur J Clin Pharmacol; 2015 Sep; 71(9):1155-7. PubMed ID: 26115613
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P; Paul E; Huang C; Headon B; Sparrow MP
    Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of pneumonia among patients with inflammatory bowel disease: a comparison between patients treated with biologic therapies and with conventional drugs.
    Romano C; Sinagra E; Criscuoli V; Orlando A; Maisano S; Cottone M
    J Crohns Colitis; 2013 Oct; 7(9):e405-6. PubMed ID: 23764367
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world evidence for vedolizumab: Understanding the landscape.
    Lawrance IC; Pulusu SSR
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():28-29. PubMed ID: 30187556
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.
    O'Toole A; Moss AC
    Curr Gastroenterol Rep; 2015 Aug; 17(8):32. PubMed ID: 26188882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
    Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on anti-TNF agents in ulcerative colitis.
    Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
    Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Biosimilars [Inflectra®] in the Management of Acute Severe Ulcerative Colitis.
    Harkin G; Keogh Á; Slattery E
    J Crohns Colitis; 2017 Oct; 11(11):1400-1401. PubMed ID: 28444254
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.